Atomoxetine and Huntington's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Huntington Disease, Chorea

In brief

The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements in subjects with early Huntington Disease (HD) and attention deficit disorder (ADD).

Key facts

Study ID

NCT00368849

Run by

University of Iowa

People needed

20

Starts

2005-11-01

Expected to finish

2008-02-01

Last updated by the study team

2012-12-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed Huntington's disease (HD) diagnosis
• Age 18 to 65
• Must have mild HD
• Must have complaints of poor attention

You may not qualify if…

• Childhood history of attention deficit hyperactivity disorder (ADHD) symptoms
• Diagnosis of schizophrenia, bipolar affective disorder, dementia, delirium or severe anxiety
• Current use of a monoamine oxidase inhibitor (MAOI) medication
• Pregnancy
• Uncontrolled hypertension
• Tachycardia
• Cardiovascular or cerebrovascular disease
• History of a loss of consciousness for greater than (or equal to) 5 minutes
• Having any neurological disorder or insult other than Huntington disease

Where it is running

• The University of Iowa — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.